422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018)
| Autor: | Damato, A., Bergamo, F., Antonuzzo, L., Nasti, G., Pietrantonio, F., Tonini, G., Maiello, E., Bordonaro, R., Bilancia, D., Romagnani, A., Iachetta, F., Larocca, M., Maglietta, G., Normanno, N., Pinto, C. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S728-S728 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|